Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | LPL | P06858 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953635 | 1.00 | TRPA1 (0.56) | TRPA1TP53TDP1ALOX15HSD17B10 | |
| SCHEMBL12394515 | 0.83 | TRPA1 (0.54) | TRPA1TP53TDP1ALOX15HSD17B10 | |
| SCHEMBL1684521 | 0.80 | TRPA1 (0.56) | TRPA1TP53TDP1ALOX15HSD17B10 | |
| SCHEMBL7776306 | 0.80 | TRPA1 (0.56) | TRPA1TP53TDP1ALOX15HSD17B10 | |
| SCHEMBL3460112 | 0.77 | ALDH1A1 (0.44) | TP53TDP1ALOX15HSD17B10ALDH1A1 | |
| SCHEMBL29349417 | 0.77 | CA2 (0.46) | TRPA1TP53TDP1ALOX15HSD17B10 | |
| SCHEMBL513136 | 0.77 | CA2 (0.46) | TRPA1TP53TDP1ALOX15HSD17B10 | |
| SCHEMBL16426121 | 0.75 | ENPP2 (0.46) | ALDH1A1CA2LPLLIPGKDM4E | |
| SCHEMBL1372258 | 0.73 | CA2 (0.42) | TRPA1TP53TDP1ALOX15HSD17B10 | |
| SCHEMBL391628 | 0.73 | CA2 (0.42) | TRPA1TP53TDP1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116731315-B | Boron-containing phthalonitrile resin and preparation method and application thereof | 中国科学院化学研究所 | 2024-06-21 | — | — | CN | claimed |
| CN-117368168-A | Application of boron-oxygen hexacyclic compound in detecting concentration of fluoride ions in aqueous solution | 大连工业大学 | 2024-01-09 | — | — | CN | claimed |
| CN-116731315-A | Boron-containing phthalonitrile resin and preparation method and application thereof | 中国科学院化学研究所 | 2023-09-12 | — | — | CN | claimed |
| WO-2025227032-A1 | METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| CN-119613428-A | Preparation method of high-sensitivity reversible thermochromic fluorane dye and compound | 江南大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-116731315-B | Boron-containing phthalonitrile resin and preparation method and application thereof | 中国科学院化学研究所 | 2024-06-21 | — | — | CN | disclosed |
| US-20240009212-A1 | PHOSPHAPLATIN COMPOUNDS AS THERAPEUTIC AGENTS SELECTIVELY TARGETING HIGHLY GLYCOLYTIC TUMOR CELLS AND METHODS THEREOF | PROMONTORY THERAPEUTICS INC. (US) | 2024-01-11 | — | — | US | disclosed |
| CN-117368168-A | Application of boron-oxygen hexacyclic compound in detecting concentration of fluoride ions in aqueous solution | 大连工业大学 | 2024-01-09 | — | — | CN | disclosed |
| CN-116731315-A | Boron-containing phthalonitrile resin and preparation method and application thereof | 中国科学院化学研究所 | 2023-09-12 | — | — | CN | disclosed |
| US-11697657-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-20220324880-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| US-6177419-B1 | ANTIOXIDANT CHELATE COMPOUNDS FOR PREVENTING OXYGEN FREE RADICAL-ASSOCIATED DISEASES IN MAMMALS; NEUROPROTECTANTS, SUPEROXIDE DISMUTASE (SOD), CATALASE (CAT) AND/OR PEROXIDASE (POD) MIMETICS | EUKARION, INC. | 2001-01-23 | — | — | US | disclosed |
| WO-2000009512-A2 | BIPYRIDINE MANGANESE COMPLEXES | EUKARION, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| EP-0758243-A4 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWISa | TEXAS BIOTECHNOLOGY CORP (US) | 1997-08-20 | — | — | EP | disclosed |
| EP-0758243-A1 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWISa | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995029682-A1 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWIS?a¿ | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1995-11-09 | — | — | WO | disclosed |
| EP-0462980-A4 | PLATINUM PHARMACEUTICAL AGENTS | — | 1992-03-11 | — | — | EP | disclosed |
| EP-0462980-A1 | PLATINUM PHARMACEUTICAL AGENTS | GEORGETOWN UNIVERSITY (US) | 1992-01-02 | — | — | EP | disclosed |
| US-4946954-A | ANTICARCINOGENIC AGENTS | GEORGETOWN UNIVERSITY (US) | 1990-08-07 | — | — | US | disclosed |
| WO-1990008157-A1 | PLATINUM PHARMACEUTICAL AGENTS | GEORGETOWN UNIVERSITY (US) | 1990-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009212-A1 | PHOSPHAPLATIN COMPOUNDS AS THERAPEUTIC AGENTS SELECTIVELY TARGETING HIGHLY GLYCOLYTIC TUMOR CELLS AND METHODS THEREOF | PHGDH, HIF1A, HIF1AN | TRPA1 2939/4885TP53 107/4885TDP1 3095/4885 |
| US-20220324880-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCA1, SMARCE1, PBRM1 | TRPA1 4874/4885TP53 858/4885TDP1 1583/4885 |
| US-11697657-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | TRPA1 4550/4885TP53 4/4885TDP1 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.